MA3 Adherence and Patient Reported Outcomes in Rheumatoid Arthritis Patients Receiving Biologic Medications: Analysis of Specialty Pharmacy Program Data  by Olvey, EL et al.
A8  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
tematic literature review was conducted to identify articles published in English 
language journals that evaluated the rate of adherence to medications in patients 
with chronic disease. Relevant studies were identified using PubMed, EMBASE, and 
the Cochrane Library databases with a search window from January 2002 through 
August 2013. Twenty-two observational studies reporting adherence were identified 
by two independent reviewers. Of these publications, 7 reported complete informa-
tion on relevant endpoints of studies in patients with osteoporosis. Meta-analyses 
examined 1) mean difference (MD) in adherence (defined using average medica-
tion possession ratio [MPR]) between QW and QD dosing groups and 2) odds ratio 
for adherence (defined using a cut-off of MPR ≥ 80%) for QW versus QD dosing. 
Heterogeneity was assessed using I42 values and meta-analyses utilized both fixed 
and random effects models. Results: The random effects meta-analysis revealed a 
significantly greater MPR with QW compared to QD dosing (pooled MD= 12.29% [95% 
confidence interval (CI) 10.76%-13.82%]; n= 9 [data reported in 7 publications]). Due 
to the high level of heterogeneity (I2= 83.4%), the fixed effects model results are not 
appropriate to report for the pooled MD. When examining the odds ratio for adher-
ence, both fixed and random effects models provided similar results due to the low 
level of heterogeneity (I2= 7.9%; n= 5 [data reported in 3 publications]). Using either 
model, the pooled odds of being adherent (MPR ≥ 80%) in the QW dosing group was 
approximately 1.9 times the odds in the QD dosing group (random effects OR= 1.90 
[95% CI 1.81-2.00]; fixed effects OR= 1.92 [95% CI 1.84-1.99]). ConClusions: In our 
meta-analysis, QW dosing was associated with higher MPR values and greater odds 
of adherence compared to QD dosing in patients with osteoporosis.
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objeCtives: Increasing morbidity related to Clostridium difficile infection (CDI) moti-
vates methods to identify patients for preventive measures. We developed a risk 
score that can be calculated automatically upon hospital admission based on an 
electronic health record and used by inpatient pharmacists to identify patients who 
would benefit from antibiotic review and patient education. Methods: We assem-
bled a cohort of Kaiser Permanente Northwest patients with a hospital admission 
between 2005 and 2012 and identified CDIs in the six months following admission, 
inclusive of the initial hospitalization. Using Cox regression, we synthesized a priori 
predictors into a risk score, in which a higher number of points indicated higher risk 
for CDIs. We plotted the observed six-month CDI risk for each decile of predicted 
risk. Results: We identified 721 CDIs in the six months following 54,186 hospital 
admissions, an incidence of 13.8 CDIs per 1000 patients. Patients with the highest 
predicted CDI risk had an observed incidence of 53 CDIs per 1000 patients--more 
than 25 times higher than the lowest-risk decile. Pre-admission patient charac-
teristics that doubled the risk of CDI, were age 40 years or greater; use of high-risk 
antibiotics; chronic kidney disease requiring dialysis; liver disease; and more than 
7 days of hospitalization within 60 days. The score differentiated patients who 
develop CDI, an extended C-statistic of 0.75. Predicted risk for CDI agreed closely 
with observed risk. ConClusions: Our risk score accurately predicted risk for CDI 
using pre-admission characteristics. Accurate predictions among the highest-risk 
subgroup of patients allow for the identification of patients who could be targeted 
for and who would likely benefit from pharmacist review of inpatient antibiotic 
use or educational efforts at the time of discharge planning, an improvement over 
simpler stratification strategies (e.g., class of antibiotic).
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objeCtives: To determine the association between warfarin discontinuation and 
stroke risk among patients with non-valvular atrial fibrillation (NVAF). Methods: 
This is a historical cohort study of adult patients (≥ 18 years of age) with NVAF 
who were on warfarin in the MarketScan Commercial and Medicare Supplemental 
Claims and Encounters Database (01/2008-06/2012). Warfarin discontinuation was 
defined as a gap of ≥ 45 days in warfarin prescription within 1 year after initiation. 
Patients with and without warfarin discontinuation were matched at a 1:1 ratio 
using a propensity score method. Matched patients were followed for up to one year 
to determine risks of ischemic stroke, transient ischemic attack (TIA), and hemor-
rhagic stroke. Patient follow-up started from the discontinuation dates for discontin-
ued patients and after the same duration of warfarin therapy for matched persistent 
patients. A multivariate Cox proportional hazards model was used to determine the 
association between warfarin discontinuation and stroke risk after adjusting for 
patient baseline demographic/clinical characteristics. Results: A total of 27,000 
discontinued and persistent patients were included in the final analysis. According 
to the descriptive analysis, discontinued patients had higher rates of ischemic stroke 
than persistent patients (0.99 vs. 0.52 per 100 patient years, P< 0.001), while the rates 
of TIA (1.15 vs. 0.93 per 100 patient years, respectively; P= 0.13) and hemorrhagic 
stroke (0.25 vs. 0.19 per 100 patient years, P= 0.31) were similar between the two 
groups. After adjusting for patient characteristics, warfarin discontinuation was 
associated with significantly increased risk of ischemic stroke (hazard ratio [HR]: 
2.04; 95% confidence interval [CI]: 1.47-2.84) and TIA (HR: 1.36; 95% CI: 1.04-1.78) 
pared health outcomes (quality of life, productivity, resource use) across adherent 
vs. non-adherent respondents. Results: 369 respondents with valid adherence 
data were included in the analyses. Mean age was 62.5 years (SD= 10.5) and most 
respondents were insured (97.6%), nonsmokers (85.9%), and unemployed or disabled 
(65.0%). 23.3% were non-adherent at z-scores> 0 (corresponding to MMAS-4> 0 and 
MMAS-8> 1), and this did not differ significantly across the treatment groups. Across 
treatments, non-adherent vs. adherent behavior was associated with significantly 
poorer health utilities (0.684 vs. 0.734, respectively), worse mental health status 
(46.0 vs. 51.9), greater impairment while working (24.2% vs. 10.5%) and overall work 
impairment (24.9% vs. 13.7%), all p< .05. Non-adherence was associated with non-
significantly higher likelihood of hospitalization in the prior 6 months (24.4% vs. 
18.0%, p= .19). ConClusions: Self-reported non-adherence to oral ET in women 
with BC was common and associated with statistically significant decrements in 
health-related quality of life, as well as work productivity impairments. Given the 
increasing use of oral ET in BC and detrimental effects of non-adherence, interven-
tions to improve adherence in those at highest risk should be developed and tested.
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objeCtives: Current practice guidelines recommend antiplatelet therapy (AT) for 
ACS patients during and after hospital discharge. Nonadherence has been associ-
ated with higher risks of thrombosis, MI and mortality. Real-world studies of AT 
adherence post-discharge have been limited by lack of access to inpatient prescrip-
tions. This study examines ACS mortality, hospital readmission, and health care 
costs by AT adherence post-discharge. Methods: Patients hospitalized for ACS 
between 7/2009-7/2012 were identified from IMS Acute Coronary Syndrome Disease 
Records, which link patient-level information from IMS PharMetrics PlusTM health 
care claims data, IMS hospital charge data master, IMS ambulatory electronic medi-
cal record and mortality data derived from the Social Security Death Index. Patients 
with no diagnosis of ACS 180 days before hospital admission, and with confirmed 
inpatient AT therapy, were followed until the earlier of 360 days post-discharge or 
date of death. Adherence was measured by receipt of AT within 30 days post-dis-
charge and by proportion of days covered (PDC) for the 360 day period post-discharge 
or up to the dates of death and readmission. Adjusted estimates controlled for 
patient demographics and CV risk measured pre-index, using logistic regression, 
Cox regression, and GLM. Results: Of 2,994 patients selected for analysis, the 1,497 
(49%) filling a script for AT within 30 days post-discharge had lower mortality (1.6% 
vs. 6.4%, p< 0.0001), readmission rates at 30 days (7.8% vs. 14.6%, p< 0.0001), and costs 
($24,772 vs. $31,691, p= 0.001) compared to patients not filling. After adjusting for 
patient characteristics, higher compliance (PDC) post-discharge was associated with 
reduced risks of mortality (HR= 0.238, 95% CI: 0.158-0.359), readmission (HR= 0.423, 
95% CI: 0.364-0.512), and lower costs (p= 0.004). ConClusions: Nonadherence with 
AT immediately after discharge and within 360 days was associated with higher 
mortality, readmissions, and costs. Study results show a significant opportunity to 
improve patient outcomes and reduce costs through higher AT adherence.
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objeCtives: To describe the adherence and patient reported outcomes (PROs) of 
rheumatoid arthritis (RA) patients taking biologic drugs enrolled in a specialty phar-
macy (SP) program. Methods: A retrospective analysis of pharmacy claims and 
PRO data for RA patients enrolled in a SP program and receiving biologic drugs from 
12/1/2011 through 10/31/2013 was conducted. Patients with a primary diagnosis of 
RA (ICD-9 CM: 714.xx) were included. Only those with at least two pharmacy claims 
and those with a baseline and at least one follow-up of PRO measures were analyzed. 
Patients who were < 18 or ≥ 90 years of age, who switched drugs or who declined 
involvement were excluded. Medication possession ratio (MPR) was used as a proxy 
for adherence and calculated based on pharmacy claims data. PROs were collected 
via telephone and included pain and fatigue measured on a numeric rating scale 
(NRS, scale: 0-10), and functional status measured using the Health Assessment 
Questionnaire-II (HAQ-II, scale: 0-3). Outcomes were collected at baseline and 
approximately every six months for the duration of the patients’ enrollment. 
Descriptive statistics, Wilcoxon signed-rank, and correlations were used to analyze 
the data. Results: A total of 2,385 patients were included. The mean age of patients 
was 54.80 years (±12.88) and 70.48% were female. The average MPR for all patients 
was 86.47% (±15.14%) over an average of 403.89 days (±167.20). Overall, 36.27% and 
38.87% of patients had at least 1-point decrease on the pain NRS and fatigue NRS, 
respectively. Any reduction in the HAQ-II score was observed in 46.79% of patients at 
follow-up, which was statistically significant (-0.065, p< 0.001). ConClusions: RA 
patients receiving biologic medications enrolled in a SP program had high therapy 
adherence and realized decreases in pain, fatigue and improvement in functional 
status from baseline.
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objeCtives: To compare medication adherence rates for once weekly (QW) versus 
once daily (QD) dosing regimens in patients with osteoporosis. Methods: A sys-
